GlassScriptPhysician profile
Ravin V Patel
NPI 1245647510
$1,088.52
in general payments reported to CMS, 2019-2025
12 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.78 · 2020: $16.66 · 2023: $66.47 · 2024: $741 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $304.32 | 2024-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $150.00 | 2024 | |
| Gilead Sciences, INC. | $122.19 | 2024 | Descovy |
| Astrazeneca Pharmaceuticals LP | $106.90 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $99.03 | 2023-2025 | |
| Intra-Sana Laboratories | $97.10 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Exact Sciences Corporation | $94.42 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $33.45 | 2025 | Spravato |
| Henry Schein, INC. | $28.89 | 2024 | |
| Glaxosmithkline, LLC. | $19.78 | 2019 | |
| Novo Nordisk INC | $16.66 | 2020 | |
| Echosens North America, INC. | $15.78 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.